Page last updated: 2024-11-04

flunitrazepam

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Flunitrazepam, also known as Rohypnol, is a benzodiazepine derivative with potent sedative, hypnotic, and amnestic properties. It was first synthesized in the 1960s by Hoffmann-La Roche. Flunitrazepam's synthesis involves multiple steps, including the reaction of a substituted benzophenone with a substituted aniline followed by cyclization and functional group modifications. Flunitrazepam acts as a positive allosteric modulator of the GABAA receptor, enhancing the effects of the neurotransmitter GABA, leading to increased chloride ion influx into neurons and hyperpolarization. This hyperpolarization results in a reduction in neuronal activity, producing the sedative, hypnotic, and amnestic effects. Flunitrazepam is primarily used for treating insomnia, anxiety disorders, and pre-operative sedation. However, its abuse potential due to its potent amnestic effects has raised concerns. Flunitrazepam has been implicated in cases of sexual assault and other crimes, leading to strict regulations and control measures. The study of flunitrazepam is important for understanding its pharmacological properties, its therapeutic applications, and its potential for misuse and abuse. Researchers investigate its synthesis pathways, receptor interactions, metabolic pathways, and the mechanisms of its adverse effects. This research helps develop safer and more effective treatments for sleep disorders and anxiety, as well as strategies to combat its abuse.'

Flunitrazepam: A benzodiazepine with pharmacologic actions similar to those of DIAZEPAM that can cause ANTEROGRADE AMNESIA. Some reports indicate that it is used as a date rape drug and suggest that it may precipitate violent behavior. The United States Government has banned the importation of this drug. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

flunitrazepam : A 1,4-benzodiazepinone that is nitrazepam substituted by a methyl group at position 1 and by a fluoro group at position 2'. It is a potent hypnotic, sedative, and amnestic drug used to treat chronic insomnia. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3380
CHEMBL ID13280
CHEBI ID31622
SCHEMBL ID44169
MeSH IDM0008590

Synonyms (89)

Synonym
flunipam
flunitrazepamum
620x0222fq ,
5-24-04-00350 (beilstein handbook reference)
roipnol
silece
unii-620x0222fq
nsc708829
nsc-708829
DIVK1C_000981
KBIO1_000981
5-(2-fluorophenyl)-1-methyl-7-nitro-1,3-dihydro-2h-1,4-benzodiazepin-2-one
rohypnol
narcozep
1,3-dihydro-5-(o-fluorophenyl)-1-methyl-7-nitro-2h-1,4-benzodiazepin-2-one
dea no. 2763
brn 0702691
1-methyl-7-nitro-5-(2-fluorophenyl)-3h-1,4-benzodiazepin-2(1h)-one
primun
hsdb 6960
ccris 5287
flunitrazepam [usan:inn:ban:jan]
einecs 216-597-8
flunitrazepamum [inn-latin]
ro 5-4200
ro-5-4200
flunitrazepam
2h-1,4-benzodiazepin-2-one, 1,3-dihydro-5-(2-fluorophenyl)-1-methyl-7-nitro-
2h-1,4-benzodiazepin-2-one, 5-(2-fluorophenyl)-1,3-dihydro-1-methyl-7-nitro-
ro54200
fluninoc
fluridrazepam
IDI1_000981
5-(2-fluorophenyl)-1-methyl-7-nitro-2,3-dihydro-1h-1,4-benzodiazepin-2-one
[3h]rohypnol
bdbm25878
chembl13280 ,
[3h]flunitrazepam
DB01544
5-(o-fluorophenyl)-1,3-dihydro-1-methyl-7-nitro-2h-1,4-benzodiazepin-2-one
rohypnol (tn)
D01230
flunitrazepam (jp17/usan/inn)
1622-62-4
NINDS_000981
n05cd03
ro-54200
HMS503E03
AKOS005066009
5-(2-fluorophenyl)-1-methyl-7-nitro-3h-1,4-benzodiazepin-2-one
A810363
5-(2-fluorophenyl)-1-methyl-7-nitro-1h-benzo[e][1,4]diazepin-2(3h)-one
flunitrazepan
MLS003899224
smr000058981
5-(2-fluorophenyl)-1,3-dihydro-1-methyl-7-nitro-2h-1,4-benzodiazepin-2-one
gtpl4193
gtpl4360
flunitrazepam [ep monograph]
flunitrazepam [who-dd]
flunitrazepam [hsdb]
flunitrazepam [inn]
flunitrazepam [usan]
flunitrazepam [jan]
flunitrazepam [mi]
flunitrazepam [mart.]
SCHEMBL44169
1,3-dihydro-5-(2-fluorophenyl)-1-methyl-7-nitro-2h-1,4-benzodiazepin-2-one
5-(2-fluorophenyl)-1-methyl-7-nitro-3h-1,4-benzodiazepin-2(1h)-one
W-107962
flunidazepam
5-(2-fluorophenyl)-1-methyl-7-nitro-1,3-dihydrobenzo[e][1,4]diazepin-2-one
5-(2-fluorophenyl)-1-methyl-7-nitro-1,3-dihydro-2h-1,4-benzodiazepin-2-one #
DTXSID7023065
fluscand
CHEBI:31622
hipnosedon
valsera
flunita
hypnor
hypnodorm
primum
flunitrazepam, european pharmacopoeia (ep) reference standard
flunitrazepam-13c6, 100 mug/ml in methanol, certified reference material
flunitrazepam 0.1 mg/ml in methanol
flunitrazepam 1.0 mg/ml in methanol
(e)-5-(2-fluorophenyl)-1-methyl-7-nitro-1h-benzo[e][1,4]diazepin-2(3h)-one
Q62947
flunitrazepam, 1mg/ml in methanol

Research Excerpts

Overview

Flunitrazepam (FNZ) is a potent hypnotic, sedative, and amnestic drug used to treat severe insomnia. It is a benzodiazepine derivative whose hypnotic effect predominates over the sedative,. anxiolytic, muscle-relaxing and anticonvulsant effects characteristic of Benzodiazepines.

ExcerptReferenceRelevance
"Flunitrazepam is an extremely potent benzodiazepine sedative which is associated with "drug-facilitated sexual assault" when administered within an alcoholic drink. "( Rapid Drop-Volume Electrochemical Detection of the "Date Rape" Drug Flunitrazepam in Spirits Using a Screen-Printed Sensor in a Dry-Reagent Format.
Diamanteas, K; Economou, A; Kokkinos, C; Papadopoulos, F, 2020
)
2.24
"Flunitrazepam is a newer benzodiazepine that is preferentially used recreationally and to facilitate sexual assault."( Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank.
Doyno, CR; White, CM, 2021
)
1.57
"Flunitrazepam (FNZ) is a potent hypnotic, sedative, and amnestic drug used to treat insomnia and as a pre-anesthetic agent. "( Metabolic Profile of Flunitrazepam: Clinical and Forensic Toxicological Aspects.
Dinis-Oliveira, RJ, 2017
)
2.22
"Flunitrazepam (FNZ) is a potent hypnotic, sedative, and amnestic drug used to treat severe insomnia. "( Characterization and tentative identification of new flunitrazepam metabolites in authentic human urine specimens using liquid chromatography-Q exactive-HF hybrid quadrupole-Orbitrap-mass spectrometry (LC-QE-HF-MS).
Liu, Y; Lu, J; Qiao, J; Qin, S; Wang, Y; Xin, G; Xu, D; Xu, Z; Zhang, W; Zhang, Y, 2019
)
2.21
"Flunitrazepam is a potent benzodiazepine that is subject to abuse and malicious use. "( Flunitrazepam abuse and malicious use in Texas, 1998-2003.
Forrester, MB, 2006
)
3.22
"Flunitrazepam is a benzodiazepine derivative whose hypnotic effect predominates over the sedative, anxiolytic, muscle-relaxing and anticonvulsant effects characteristic of benzodiazepines. "( Flunitrazepam: a review of its pharmacological properties and therapeutic use.
Larni, HM; Mattila, MA, 1980
)
3.15
"Flunitrazepam appears to be a useful alternative anesthesia-induction agent that prevents some of the side effects of succinylcholine without reducing its efficiency."( Intravenous flunitrazepam in the prevention of the side effects of succinylcholine.
Aronson, HB; Vatashsky, E, 1982
)
1.36
"Flunitrazepam appears to be a narcohypnotic of choice in ophthalmological surgery on these inherently debilitated patients."( [Effects of flunitrazepam on intraocular pressure (author's transl)].
Deligne, P; Forest, A; Girard, P; Maillet, J; Perier, JF, 1982
)
1.36
"The flunitrazepam is a benzodiazepine with hypnotic, ansiolytic and miorelaxant properties, which has been used as an anaesthetic in major and minor surgery."( [Medication with flunitrazepam in electroconvulsive therapy].
Birkner, R; Durán, E; Ercilla, R; Schilkrut, R, 1980
)
1.08
"Flunitrazepam is a benzodiazepine that fulfills all these criteria."( Intravenous flunitrazepam in the treatment of alcohol withdrawal delirium.
Barnas, C; Fleischhacker, WW; Hummer, M; Miller, C; Pycha, R; Stuppäck, C; Whitworth, A, 1993
)
1.39
"Flunitrazepam is a benzodiazepine of long half-life with sedative, anxiolytic, muscle relaxant and anticonvulsant properties. "( Flunitrazepam in terminal care.
Sanders, HG; Smales, EA; Smales, OR, 1993
)
3.17
"Flunitrazepam is an hypnotic benzodiazepine marketed in different European countries. "( A comparison of the acute behavioral effects of flunitrazepam and triazolam in healthy volunteers.
Camí, J; Farré, M; Terán, MT, 1996
)
1.99
"Flunitrazepam (Rohypnol) is a benzodiazepine sedative-hypnotic that has generated significant media attention in the United States because of its abuse and its association with "date rape." A field investigation was conducted in south Texas to ascertain the nature and consequences of the abuse of flunitrazepam. "( Abuse of flunitrazepam (Rohypnol) and other benzodiazepines in Austin and south Texas.
Calhoun, SR; Galloway, GP; Smith, DE; Wesson, DR,
)
1.99
"Flunitrazepam (Rohypnol) is a benzodiazepine used in the treatment of insomnia as a sedative hypnotic and as preanesthetic medication in European countries and Mexico. "( Highly sensitive micro-plate enzyme immunoassay screening and NCI-GC-MS confirmation of flunitrazepam and its major metabolite 7-aminoflunitrazepam in hair.
Deitermann, D; Feeley, B; Kaleciak, K; Kronstrand, R; Lewis, D; Moore, C; Negrusz, A; Niedbala, RS, 1999
)
1.97
"Flunitrazepam is a potent benzodiazepine."( Club drugs: methylenedioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate.
Larive, LL; Romanelli, F; Smith, KM, 2002
)
1.3
"Flunitrazepam is a new oral premedicant with prominent sedative and anxiolytic actions."( Flunitrazepam versus placebo premedication for minor surgery.
Kangas, L; Kanto, J; Mansikka, M, 1979
)
2.42
"3H-Flunitrazepam is a very suitable ligand for affinity binding and it binds to the same class of binding sites as 3H-diazepam."( Brain specific benzodiazepine receptors.
Braestrup, C; Squires, RF, 1978
)
0.77
"Flunitrazepam is a benzodiazepine with pronounced hypnotic effects in the usual dosage."( High-dose flunitrazepam anesthesia.
Eldor, J, 1992
)
1.41
"Flunitrazepam is a well-known hypnotic, binding to both the benzodiazepine 1 and 2 receptor subtypes."( Effects of zolpidem and flunitrazepam on nocturnal sleep of women subjectively complaining of insomnia.
Declerck, AC; O'Hanlon, JF; Ruwe, F; Vermeeren, A; Wauquier, A, 1992
)
1.31
"Flunitrazepam is a haemodynamic secure and valuable agent for sedation during recovery for patients with C.A.D."( [Hemodynamic effects of flunitrazepam in coronary patients. Postoperative study immediately after digestive tract and orthopedic surgery].
Blanloeil, Y; Bourreli, B; Deletang, S; Gunst, JP; Melchior, JC,
)
1.16

Effects

Flunitrazepam has greater potency and higher affinity for the type A GABA receptor than most benzodiazepines. It has been used as a photoaffinity label for the specific, clonazepam-displaceable 1,4-benzodiazepine binding sites in sections of normal brain and spinal cord.

ExcerptReferenceRelevance
"Flunitrazepam has a faster and more extensive tissue distribution and a more rapid elimination (half-life about 12 h) in children than in adults."( Flunitrazepam as an induction agent in children. A clinical and pharmacokinetic study.
Aaltonen, L; Iisalo, E; Kanto, J; Mäkelä, J, 1984
)
2.43
"Flunitrazepam has greater potency and higher affinity for the type A GABA receptor than most benzodiazepines."( Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank.
Doyno, CR; White, CM, 2021
)
1.57
"Flunitrazepam has been reported to trigger cases of extreme violence in man and recently it was shown to heighten aggression in experimental rats. "( Chronic effects of flunitrazepam on shock-induced behavioral inhibition in adult male rats.
Svensson, AI, 2009
)
2.12
"[3H]flunitrazepam has been used as a photoaffinity label for the specific, clonazepam-displaceable 1,4-benzodiazepine binding sites in sections of normal C57BL6J mouse brain and spinal cord. "( Autoradiography of benzodiazepine receptor binding in the central nervous system of the normal C57BL6J mouse.
Biscoe, TJ; Fry, JP; Rickets, C, 1984
)
0.83
"Flunitrazepam has a faster and more extensive tissue distribution and a more rapid elimination (half-life about 12 h) in children than in adults."( Flunitrazepam as an induction agent in children. A clinical and pharmacokinetic study.
Aaltonen, L; Iisalo, E; Kanto, J; Mäkelä, J, 1984
)
2.43
"Flunitrazepam has no therapeutic advantage over benzodiazepines presently marketed in the US."( Use and abuse of flunitrazepam.
Cupp, MJ; Simmons, MM, 1998
)
1.36
"Flunitrazepam (Ro 5-4200) has been studied as an induction agent in 220 volunteers or patients. "( Clinical studies of induction agents XLIII: Flunitrazepam.
Clarke, RS; Dundee, JW; Gaston, JH; Varadarajan, CR, 1976
)
1.96

Actions

ExcerptReferenceRelevance
"4. Flunitrazepam-induced increase on wet dog shake frequency was partially reduced by flumazenil, and strongly antagonized by ritanserine and Ro 15-4513."( Study of the mechanisms involved in behavioral changes induced by flunitrazepam in morphine withdrawal.
Gibert-Rahola, J; Maldonado, R; Micó, JA; Valverde, O, 1995
)
1.04

Treatment

Flunitrazepam treatment reduced (p < 0.05) the maximal GABA-stimulated increase in extracellular acidification rate. There were no deaths after lidocaine and only one after bupivacaine.

ExcerptReferenceRelevance
"With flunitrazepam pretreatment, there were no deaths after lidocaine and only one after bupivacaine."( A comparison of flunitrazepam and diazepam in the prevention of local anesthetic-induced convulsions.
Aronson, HB; Vatashsky, E; Zaroura, S, 1983
)
1.07
"Flunitrazepam treatment reduced (p < 0.05) the maximal GABA-stimulated increase in extracellular acidification rate (Emax) (16.5 +/- 1.2% and 11.3 +/- 1.0%, 2-day control and treated cells, respectively; 17.4 +/- 1.0% and 9.9 +/- 0.7%, 7-day control and treated cells, respectively; best-fit Emax +/- SEM, n = 7), without affecting the GABA concentration required to elicit 50% of maximal response (EC50) (1.2 +/- 1.7 and 2.3 +/- 1.8 microM, 2-day control and treated cells, respectively; 1.7 +/- 1.5 and 1.5 +/- 1.5 microM, 7-day control and treated cells, respectively; best-fit EC50 +/- SEM, n = 7)."( Gamma-aminobutyric acidA receptor function is desensitised in rat cultured cerebellar granule cells following chronic flunitrazepam treatment.
Bristow, DR; Brown, MJ; Coldwell, MC; Wood, MD, 1998
)
1.23

Toxicity

ExcerptReferenceRelevance
" On several counts, the combination of ketamine and flunitrazepam was proved to reduce the adverse reactions seen with ketamine alone."( Reduction of psychotomimetic side effects of Ketalar (ketamine) by Rohypnol (flunitrazepam). A randomized, double-blind trial.
Freuchen, I; Kühl, JB; Mikkelsen, BO; Ostergaard, J, 1976
)
0.74
"This article summarizes the short-term physiological toxicity and the adverse behavioral effects of four substances (GHB, ketamine, MDMA, and Rohypnol) that have been used at latenight dance clubs."( Acute toxic effects of club drugs.
Gable, RS, 2004
)
0.32

Pharmacokinetics

The pharmacokinetic behaviour of flunitrazepam and its main active metabolite was investigated in 12 patients with liver disease (cirrhosis or hepatitis) compared to 6 healthy volunteers. The elimination phase half-life of midazolam was about twice as long as reported earlier in healthy adult volunteers.

ExcerptReferenceRelevance
"The pharmacokinetic behaviour of flunitrazepam and its main active metabolite, N-desmethyl flunitrazepam, was investigated in 12 patients with liver disease (cirrhosis or hepatitis) compared to 6 healthy volunteers."( Pharmacokinetics of flunitrazepam following single dose oral administration in liver disease patients compared with healthy volunteers.
Antoni, M; Cano, JP; Coassolo, P; Drouet-Coassolo, C; Iliadis, A, 1990
)
0.88
"The pharmacokinetic profiles of oral and sublingual administrations of prazepam 20 mg to 5 normal volunteers were compared in order to explain the clinical observation that sublingual prazepam appears to exhibit sedative properties when compared to the same dose of oral prazepam."( Comparison of sublingual and oral prazepam in normal subjects. II. Pharmacokinetic and pharmacodynamic data.
Ansseau, M; Jacqmin, P, 1988
)
0.27
"Two interactive computer programs, INTRAV and ORAL, were written to permit pharmacokinetic modeling of experimental data and to obtain pertinent values based on derived estimates."( INTRAV and ORAL: BASIC interactive computer programs for estimating pharmacokinetic parameters.
Hunter, S; Valentine, JL, 1985
)
0.27
" The elimination half-life of both flunitrazepam and loprazolam was not changed in the two conditions."( Effect of after-dinner administration on the pharmacokinetics of oral flunitrazepam and loprazolam.
Bareggi, SR; Leva, S; Pirola, R; Smirne, S; Truci, G, 1988
)
0.79
"Diazepam, flunitrazepam and midazolam have different pharmacokinetic properties, their biological halflives for instance, being 24 to 48 hours, 4,5 hours and 2,5 hours respectively."( [Clinical pharmacokinetics of midazolam, flunitrazepam and diazepam (author's transl)].
Lauven, PM; Schüttler, J; Schwilden, H; Stoeckel, H, 1981
)
0.93
" injections of flunitrazepam was constructed by mathematical simulation on the basis of pharmacokinetic data obtained from single intravenous injections given to healthy subjects."( [Clinical pharmacokinetics of flunitrazepam (Nacrozep) in intensive care patient (preliminary results)].
Cano, JP; Colavolpe, C; Granthil, C; Jean, P; Rigault, JP; Sumirtapura, Y, 1981
)
0.9
" The concentrations of unchanged flunitrazepam in sea were determined by 63Ni-EC-GLC, and the pharmacokinetic parameters were calculated using the two-compartment open model."( Effect of age on the pharmacokinetics and sedative of flunitrazepam.
Aaltonen, L; Hilke, H; Kangas, L; Kanto, J, 1981
)
0.79
"Knowledge of the pharmacokinetic properties of the benzodiazepines is playing an increasingly important role in their use during pregnancy, labour and lactation."( Use of benzodiazepines during pregnancy, labour and lactation, with particular reference to pharmacokinetic considerations.
Kanto, JH, 1982
)
0.26
" Pharmacodynamic characteristics were estimated subjectively by simple questionnaire and objectively by the anesthetist during and after anesthesia."( A pharmacokinetic and pharmacodynamic study of flunitrazepam.
Kangas, L; Kanto, J; Pakkanen, A, 1982
)
0.52
"Large differences exist among the various benzodiazepines with regard to their pharmacokinetic properties and metabolism in man."( Pharmacokinetics of benzodiazepines: metabolic pathways and plasma level profiles.
Breimer, DD; Jochemsen, R, 1984
)
0.27
" The elimination phase half-life of midazolam was about twice as long as reported earlier in healthy adult volunteers, but ageing did not affect the elimination of flunitrazepam."( Midazolam and flunitrazepam: pharmacokinetics and effects on night time respiration and body movements in the elderly.
Alihanka, J; Himberg, JJ; Kanto, J; Rajala, T; Seppälä, M; Sourander, L, 1993
)
0.84
" Despite significant elevations in triazolam plasma levels with coadministration of ketoconazole, the pharmacodynamic enhancement was lower than predicted based on plasma levels of triazolam."( Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice.
Fahey, JM; Grassi, JM; Greenblatt, DJ; Moltke, LL; Pratt, JS; Pritchard, GA; Shader, RI, 1998
)
0.3
"To study the pharmacokinetics of flunitrazepam (used for sedation in neonates and infants), to determine the influence of both gestational and postnatal age on the pharmacokinetic parameters, and to analyze the relationship between the hemodynamic parameters and flunitrazepam plasma concentration."( Pharmacokinetics and tolerance of flunitrazepam in neonates and in infants.
d'Athis, P; Hotellier, F; Hubert, P; Jouvet, P; Mokhtari, M; Olive, G; Pariente-Khayat, A; Pons, G; Rey, E; Tréluyer, JM; Werner, E; Wood, C, 1999
)
0.86
" After the single dose (n = 28), half-life was 22."( Pharmacokinetics and tolerance of flunitrazepam in neonates and in infants.
d'Athis, P; Hotellier, F; Hubert, P; Jouvet, P; Mokhtari, M; Olive, G; Pariente-Khayat, A; Pons, G; Rey, E; Tréluyer, JM; Werner, E; Wood, C, 1999
)
0.58
"Postnatal age but not gestational age influenced flunitrazepam pharmacokinetic parameters in neonates and infants."( Pharmacokinetics and tolerance of flunitrazepam in neonates and in infants.
d'Athis, P; Hotellier, F; Hubert, P; Jouvet, P; Mokhtari, M; Olive, G; Pariente-Khayat, A; Pons, G; Rey, E; Tréluyer, JM; Werner, E; Wood, C, 1999
)
0.84
"To assess pharmacodynamic and neurochemical aspects of tolerance, lorazepam (2 mg/kg/day), or vehicle was administered chronically to male Crl: CD-1(ICR)BR mice via implantable osmotic pump."( Pharmacodynamic and receptor binding changes during chronic lorazepam administration.
Fahey, JM; Grassi, JM; Greenblatt, DJ; Pratt, JS; Pritchard, GA; Shader, RI,
)
0.13
" The GC-MS method was successfully applied to the pharmacokinetic study of BUP, NBUP, FNZ, DMFNZ and 7-AFNZ in rats, after administration of BUP and FNZ."( Development and validation of a gas chromatography-mass spectrometry method for the simultaneous determination of buprenorphine, flunitrazepam and their metabolites in rat plasma: application to the pharmacokinetic study.
Baud, F; Bouchonnet, S; D'Athis, P; Hervé, F; Libong, D; Milan, N; Pirnay, S; Ricordel, I, 2004
)
0.53
" To assess pharmacodynamic and neurochemical effects of zolpidem, open-field behavior, pentylenetetrazole-induced seizure threshold and benzodiazepine receptor binding in vitro were evaluated in the same animal following a single dose of zolpidem."( Acute zolpidem administration produces pharmacodynamic and receptor occupancy changes at similar doses.
Fahey, JM; Grassi, JM; Greenblatt, DJ; Reddi, JM, 2006
)
0.33
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Compound-Compound Interactions

ExcerptReferenceRelevance
" FZ is also associated with loss of episodic memory and with impulsive violence, particularly when combined with alcohol."( Flunitrazepam (Rohypnol) abuse in combination with alcohol causes premeditated, grievous violence in male juvenile offenders.
Dåderman, AM; Lidberg, L, 1999
)
1.75
" The nanoparticle-assisted MALDI-TOF MS combined with seed-layer surface preparation provides a rapid, efficient and accurate platform for the quantification of small molecules in urine samples."( Nanoparticle-assisted MALDI-TOF MS combined with seed-layer surface preparation for quantification of small molecules.
Chen, YJ; Fuh, MR; Ho, YC; Lin, CC; Lu, YW; Tseng, MC, 2011
)
0.37

Bioavailability

The absolute and relative bioavailability of flunitrazepam (Rohypnol) tablet, oral solution and suppository formulations was determined in a cross-over study on 6 healthy volunteers.

ExcerptReferenceRelevance
" It is suitable for investigations on pharmacokinetics and bioavailability as well as for monitoring the correlation between plasma level and therapeutic efficacy and toxicology."( Determination of flunitrazepam, desmethylflunitrazepam and clonazepam in plasma by gas liquid chromatography with an internal standard.
Aubert, C; Cano, JP; Guintrand, J; Viala, A, 1977
)
0.6
"The absolute and relative bioavailability of flunitrazepam (Rohypnol) tablet, oral solution and suppository formulations was determined in a cross-over study on 6 healthy volunteers."( Bioavailability from various galenic formulations of flunitrazepam.
Amrein, R; Cano, JP; Hartmann, D; Soliva, M; Ziegler, WH, 1977
)
0.77
" Pharmacokinetics and bioavailability are certainly altered by such modifications, usually in a positive sense."( Peptide derivatives as prodrugs.
Thomas, WA, 1986
)
0.27
" In an attempt to develop therapeutic agents which would maintain the pharmacological profiles of endogeneous neuroactive steroids but with increased oral bioavailability and reduced metabolic liability, we explored simple substitutions at the 3 beta-position of the endogenous neuroactive steroid, 3 alpha-hydroxy-5 alpha-pregnan-20-one (3 alpha, 5 alpha-P)."( Anxiolytic and anticonvulsant activity of a synthetic neuroactive steroid Co 3-0593.
Belluzzi, J; Gee, KW; Hawkinson, JE; Hogenkamp, D; Lan, NC; Stein, L; Upasani, R; Wieland, S; Wood, PL, 1997
)
0.3
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" The main reason for the difference appears to be due to differences in the rate of absorption of the main drug."( [Comparative study of drug efficacy and drug additives between generic drugs and original drugs].
Katoh, H; Ozawa, K; Yoshii, M, 2007
)
0.34

Dosage Studied

There was a significant difference in the slope of log dose-response curves. These curves were much steeper for pentobarbitone, droperidol and chlorpromazine. The enhancement of [3H]flunitrazepam binding to the benzodiazepine receptor by loreclezole as well as the effect of lore Clezole on CL218872/[3H].

ExcerptRelevanceReference
" The dosage of ketamine was 2 mg/kg body weight, supplemented if necessary by 1 mg/kg, in combination with either 2 mg flunitrazepam or placebo."( Reduction of psychotomimetic side effects of Ketalar (ketamine) by Rohypnol (flunitrazepam). A randomized, double-blind trial.
Freuchen, I; Kühl, JB; Mikkelsen, BO; Ostergaard, J, 1976
)
0.69
" Sleep was invariably produced in patients receiving 4 mg but at lower dosage some patients failed to become unconscious."( Intravenous flunitrazepam as an anesthetic induction agent.
Ang, PP; Chiu, HH; Lean, TH, 1976
)
0.63
" Careful dosage of the drugs, in particular of fentanyl, and knowledge of adequate measures to treat a decrease in blood pressure if it occurs, appears to be a prerequisite for the use of this type of anaesthesia in poor risk patients."( [Anaesthesia with flunitrazepam (rohypnol) and fentanyl for geriatric patients (author's transl)].
Haldemann, G; Hossli, G; Schaer, H, 1977
)
0.59
" When lower doses or shorter dosage regimens are used, increased binding is not observed."( Increased specific binding of [3H]diazepam in rat brain following chronic diazepam administration.
Bosmann, HB; Case, KR; Colello, GD; DiStefano, P, 1979
)
0.26
" There was a significant difference in the slope of log dose-response curves; these curves were much steeper for pentobarbitone, droperidol and chlorpromazine than for nitrazepam, flunitrazepam, and diazepam."( [Action of central depressants on the nitrous oxide anesthesia (author's transl)].
Andics, A; Gogolák, G; Huck, S; Stumpf, C, 1975
)
0.45
"Dogs dosed chronically (4-7 weeks) with oral flunitrazepam (7."( A comparison of the physical dependence inducing properties of flunitrazepam and diazepam.
Martin, WR; Sloan, JW; Wala, EP, 1991
)
0.78
" Daytime sleep propensity during the day after dosing was evaluated with the multiple sleep latency test."( Daytime wakefulness following a bedtime oral dose of zolpidem 20 mg, flunitrazepam 2 mg and placebo.
Bensimon, G; Foret, J; Lacomblez, L; Simon, P; Thiercelin, JF; Warot, D, 1990
)
0.51
" Hill coefficients, determined from dose-response data, indicated that binding of at least two GABA molecules was required to activate the chloride channel."( GABA receptors on the cell-body membrane of an identified insect motor neuron.
David, JA; Pinnock, RD; Sattelle, DB; Wafford, KA, 1988
)
0.27
" Enhancement of submaximal GABA responses by benzodiazepines was demonstrated using a multibarrel pipette to construct complete benzodiazepine dose-response curves for single cells in culture."( Benzodiazepine interactions with GABAA receptors on chick ciliary ganglion neurons.
Berg, DK; McEachern, AE, 1988
)
0.27
" Dosing lasted 7 days."( Saccadic eye movements as a measure of residual effects: temazepam compared with other hypnotics.
Hofferberth, B, 1986
)
0.27
" The results suggest that the extent of the benzodiazepines' amnesic effects--both negative (anterograde) and positive (retrograde)--depends on the dosage and type of substance."( Anterograde and retrograde amnesia after lormetazepam and flunitrazepam.
Aufdembrinke, B; Fichte, K; Ott, H; Rohloff, A, 1988
)
0.52
" In qualitative agreement with reversible binding data the dose-response curve for enhancement of the GABA response by benzodiazepines was shifted to the right, indicating that the remaining reversible benzodiazepine binding sites have lower affinity for benzodiazepines."( Benzodiazepine receptor photoaffinity labeling: correlation of function with binding.
Chan, CY; Czajkowski, CM; Farb, DH; Gibbs, TT, 1985
)
0.27
" The repeated dosing decreased body weight and caused neuromuscular dysfunction."( 3H-dopamine uptake and 3H-haloperidol binding in striatum after administration of methyl mercury to rats.
Komulainen, H; Tuomisto, J, 1985
)
0.27
" In a dose-response experiment for melatonin ability to restore the depressed BZP receptor concentration of cerebral cortex membranes of pinealectomized rats killed at noon, a minimal effective dose of 25 micrograms/kg body weight was obtained."( Diurnal variations of benzodiazepine binding in rat cerebral cortex: disruption by pinealectomy.
Acuña-Castroviejo, D; Cardinali, DP; Lowenstein, PR; Rosenstein, R, 1986
)
0.27
" The shape of the muscimol dose-response curve was shallow, suggestive of negative cooperativity or heterogeneous receptors, but tissue uptake of agonist, possible diffusion barriers and apparent functional desensitization complicated these results."( gamma-Aminobutyric acid receptor-regulated 36Cl- flux in mouse cortical slices.
Olsen, RW; Yang, JS, 1987
)
0.27
" We concluded that there are no major differences between the three drugs in the dosage used."( Diazepam, flunitrazepam and midazolam for elective endoscopy--a comparative study.
Badran, I; Hunjul, N; Sbeih, Z; Takrouri, MS; Toukan, A, 1988
)
0.68
" We tested the dosage of drugs needed in relation to the length of treatment, the size of the stone and the overall energy output of the lithotriptor."( [Extracorporeal shockwave lithotripsy in sedation-analgesia].
Berger, M; Brandstetter, A; Chowanetz, E; Gasser, G; Mossig, H; Schmidt, P, 1988
)
0.27
" Pharmacokinetics should underlie the rational use of drugs and when a therapeutic range is known, the achievement of safe and effective target concentrations may be assured by a dosage regimen computed for a given administration schedule."( Dynamical dosage regimen calculations in linear pharmacokinetics.
Bruno, R; Cano, JP; Iliadis, A, 1988
)
0.27
" The dose-response curve of flunitrazepam, a benzodiazepine derivative, was investigated by using PPR in the present study."( A useful tool for predicting the clinical effects of hypnotics in humans: averaged photopalpebral reflex.
Hamasaki, J; Hirano, H; Imaizumi, J; Inanaga, K; Mizuki, Y; Tanaka, M; Ushijima, I; Yamada, M, 1986
)
0.57
" Although the safe dosage range is wide with flunitrazepam, its effective application both as a hypnotic for insomnia and in anaesthesiology is dependent upon use of the optimal dosage, and adequate knowledge of its pharmacokinetic properties."( Flunitrazepam: a review of its pharmacological properties and therapeutic use.
Larni, HM; Mattila, MA, 1980
)
1.96
" The initial dosage of half a tablet was sufficient and was maintained in 13 patients."( [Study of flunitrazepam in the insomnia of the aged (author's transl)].
Ducreuzet, C,
)
0.53
" It is concluded that both active drugs were highly effective, with a minimum of side effects, in this type of insomnia and with the relatively low dosage used."( Triazolam (Halcion) versus flunitrazepam (Rohypnol) against midwinter insomnia in Northern Norway.
Bratlid, T; Lingjaerde, O, 1981
)
0.56
" Such differences may be very important clinically because pharmacokinetic data will help to optimize drug therapy with respect to the choice of the proper drug and drug preparation, as well as with the choice of a proper dose and dosage regimen."( Pharmacokinetics of benzodiazepines: metabolic pathways and plasma level profiles.
Breimer, DD; Jochemsen, R, 1984
)
0.27
" After chronic dosing the sedative effects of flunitrazepam showed tolerance and the increases in exploration remained while locomotion was less increased."( Effects of agents which enhance GABA-mediated neurotransmission on licking conflict in rats and exploration in mice.
Gardner, CR; Piper, DC, 1982
)
0.52
" A new technique was developed to permit the determination of complete electrophysiological dose-response curves on single neurons in cell culture, eliminating cell-to-cell variability as a problem that complicates the interpretation of pooled data."( Multiple embryonic benzodiazepine binding sites: evidence for functionality.
Borden, LA; Chan, CY; Farb, DH; Gibbs, TT, 1983
)
0.27
" The EEG is a proven parameter with regard to dosage determination and as objective means to find sleep-inducing quantities of drugs."( Modern trends in the investigation of new hypnotics in anaesthesia.
Doenicke, A, 1984
)
0.27
"The combination of fentanyl and droperidol, Innovar, was compared to flunitrazepam (1-2 mg) in a higher dosage (2."( [High-dose thalamonal-rohypnol for premedication. A randomized double-blind study].
Schmidt, R; Tolksdorf, W; Wagener, M, 1984
)
0.5
" Adapting dosage to size (0."( [Hyperbaric spinal anesthesia with 0.5 percent bupivacaine in traumatological and orthopedic surgery].
Boittiaux, P; Scherpereel, P; Snauwaert, F, 1984
)
0.27
" Their ED50 values were determined from their dose-response curves."( A new method for the evaluation of benzodiazepines based on their ability to block muscimol-induced myoclonic jerks in mice.
Haddox, VG; Menon, MK; Vivonia, CA, 1981
)
0.26
" The EC50 obtained from the dose-response curves for GABA in eliciting a maximal response was comparable in neurons maintained in high K+ or in low K+ and treated with a single dose of NMDA, but that it increased significantly in cells maintained in low K+."( NMDA-mediated modulation of gamma-aminobutyric acid type A receptor function in cerebellar granule neurons.
Grayson, DR; Harris, BT; Vicini, S; Zhu, WJ, 1995
)
0.29
" However, a 10-fold increase in dosage produced a mild sedative effect since a 26% reduction in ambulatory locomotor activity and a 35% decrement in hole-board parameters were evident."( Apigenin, a component of Matricaria recutita flowers, is a central benzodiazepine receptors-ligand with anxiolytic effects.
Dajas, F; Levi de Stein, M; Medina, JH; Paladini, AC; Silveira, R; Viola, H; Wasowski, C; Wolfman, C, 1995
)
0.29
"4 the GABA dose-response curve indicates that the increases in the peak current are related to an augmented maximal current."( Modulation by extracellular pH of the activity of GABAA receptors on rat cerebellum granule cells.
Baldelli, P; Cupello, A; Robello, M, 1994
)
0.29
" Alzet 2001 osmotic pumps deliver at a constant rate (1 microliter/h) and dosage can be easily adjusted."( A system for testing the development and reversal of anticonvulsant tolerance to benzodiazepines in mice.
Kapetanovic, IM; Kupferberg, HJ; Torchin, CD, 1993
)
0.29
" 15 patients received diazepam and 20 were given flunitrazepam in a dosage of 10 and 1 mg respectively."( [Effect of sedation on otoacoustic emissions].
Andes, C; Delb, W; Koch, A; Merl, E, 1994
)
0.54
" Diazepam shifted the dose-response curve for muscimol-stimulated flux to about 4-fold lower concentrations without affecting the maximum response."( Reconstitution of purified GABAA receptors: ligand binding and chloride transporting properties.
Dunn, SM; Thuynsma, RP, 1994
)
0.29
" Thus, bicuculline not only produced a rightward shift of the dose-response curves of the central depressant drugs in the cortex, but also increased the maximal stimulation of 35S-TBPS binding."( Bicuculline-produced regional differences in the modulation of 35S-TBPS binding by GABA, pentobarbital and diazepam in mouse cerebellum and cortex.
Liljequist, S; Tabakoff, B, 1993
)
0.29
", owing to the higher dosage used in our study (50 mg as against 20 mg)."( [Oral premedication with clorazepate dipotassium. Comparison with oral premedication with flunitrazepam and intramuscular premedication with promethazine, pethidine and atropine in adults].
Gonzales, I; Kretz, FJ; Peidersky, P, 1993
)
0.51
" The enhancement of [3H]flunitrazepam binding to the benzodiazepine receptor by loreclezole as well as the effect of loreclezole on CL218872/[3H]flunitrazepam dose-response curves suggest that loreclezole does not act through the benzodiazepine site on the GABAA receptor complex, nor does it selectively modulate benzodiazepine receptor subtypes."( Loreclezole modulates [35S]t-butylbicyclophosphorothionate and [3H]flunitrazepam binding via a distinct site on the GABAA receptor complex.
Friend, JM; Gee, KW; Xue, BG, 1996
)
0.84
" In aged rats, the dose-response curve was shifted to the left, indicating an increase in the potency of GABA to inhibit [3H]t-butylbicycloorthobenzoate binding."( GABAA receptor binding in the aging rat inferior colliculus.
Albin, RL; Caspary, DM; Milbrandt, JC; Turgeon, SM, 1996
)
0.29
" Chronic dosing with minaxolone (100 mg/kg, orally, once daily for 7 days) resulted in a loss of sedative response to an acute dose of the drug, indicating development of tolerance."( Development of tolerance in mice to the sedative effects of the neuroactive steroid minaxolone following chronic exposure.
Ford, E; Hagan, RM; Marshall, FH; Mullings, J; Oakley, NR; Stratton, SC; Worton, SP, 1997
)
0.3
" Dose-response curves for the peak and the slow component yielded EC50 values of 139 and 24 microM, respectively."( Dentate gyrus basket cell GABAA receptors are blocked by Zn2+ via changes of their desensitization kinetics: an in situ patch-clamp and single-cell PCR study.
Berger, T; Kraushaar, U; Monyer, H; Schwarz, C, 1998
)
0.3
" were subcutaneously injected in two-day-old chicks and a dose-response curve assessed for escape performance in a T-maze test."( Anxiogenic-like effects of Tagetes minuta L essential oil on T-maze and tonic immobility behaviour in domestic chicks.
Arce, A; Garcia, DA; Marin, RH; Martijena, ID; Perillo, MA; Zygadlo, JA, 1998
)
0.3
" The effects on psychomotor sedation, attention, working memory and explicit memory were then assessed at various intervals after dosing and compared with levels of the drug in the plasma."( Impairment of memory and plasma flunitrazepam levels.
Bareggi, SR; Ferini-Strambi, L; Pirola, R; Smirne, S, 1998
)
0.58
" In an attempt to further clarify the mechanisms underlying these degeneration patterns, autoradiographic studies using a variety of receptor ligands were conducted in animals 21 days after an identical dosage of the continuous phencyclidine administration employed in the previous degeneration studies."( Long-term changes in brain following continuous phencyclidine administration: an autoradiographic study using flunitrazepam, ketanserin, mazindol, quinuclidinyl benzilate, piperidyl-3,4-3H(N)-TCP, and AMPA receptor ligands.
Ellison, G; Keys, A; Noguchi, K, 1999
)
0.52
"Symptoms of the autonomic nervous system were more effectively prevented by GHB as evident in the lower dosage requirement of clonidine."( [Gamma-hydroxybutyrate for treatment of alcohol withdrawal syndrome in intensive care patients. A comparison between with two symptom-oriented therapeutic concepts].
Lenzenhuber, E; Müller, C; Rommelspacher, H; Spies, C, 1999
)
0.3
"The present study examined the dose-response relationships between acute flunitrazepam administration and human decision making under conditions of risk."( Modulation of human risky decision making by flunitrazepam.
Cherek, DR; Lane, SD; Nouvion, SO, 2008
)
0.84
" Dose-response functions determined with both training compounds revealed a clear dissociation between the discriminative stimulus effects of these drugs."( Differentiating the discriminative stimulus effects of gamma-hydroxybutyrate and ethanol in a three-choice drug discrimination procedure in rats.
Baker, LE; Poling, A; Pynnonen, DM; Searcy, GD, 2008
)
0.35
" Information for health professionals and workers in forensic structures as well as education of the general population associated with preventive measures such as drug dosage form changes should contribute to improved care management of victims and decreased risk."( Chemical submission: results of 4-year French inquiry.
Burin, E; Dally, S; Djezzar, S; Questel, F, 2009
)
0.35
" Data on occurrence of CSB, demographic characteristics, flunitrazepam dosage and duration of use, psychiatric diagnoses, physical illnesses, and alcohol use were collected."( Prevalence and clinical correlates of flunitrazepam-related complex sleep behaviors.
Chang, YP; Chen, CS; Chen, ST; Chen, TT; Hwang, TJ; Ko, CH; Lin, JJ; Su, PW; Tsai, JK; Yen, CF; Yen, CN, 2017
)
0.97
" Logistic regression analysis showed that a high dosage (>2 mg/day) of flunitrazepam (odds ratio [OR] = 1."( Prevalence and clinical correlates of flunitrazepam-related complex sleep behaviors.
Chang, YP; Chen, CS; Chen, ST; Chen, TT; Hwang, TJ; Ko, CH; Lin, JJ; Su, PW; Tsai, JK; Yen, CF; Yen, CN, 2017
)
0.96
"CSB among flunitrazepam users should be monitored routinely, especially among those receiving a high dosage who also consume alcohol."( Prevalence and clinical correlates of flunitrazepam-related complex sleep behaviors.
Chang, YP; Chen, CS; Chen, ST; Chen, TT; Hwang, TJ; Ko, CH; Lin, JJ; Su, PW; Tsai, JK; Yen, CF; Yen, CN, 2017
)
1.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
sedativeA central nervous system depressant used to induce drowsiness or sleep or to reduce psychological excitement or anxiety.
GABAA receptor agonistA GABA receptor agonist specific for GABAA receptors, ligand-gated ion channels (also known as ionotropic receptors).
anxiolytic drugAnxiolytic drugs are agents that alleviate anxiety, tension, and anxiety disorders, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
1,4-benzodiazepinone
C-nitro compoundA nitro compound having the nitro group (-NO2) attached to a carbon atom.
monofluorobenzenesAny member of the class of fluorobenzenes containing a mono- or poly-substituted benzene ring carrying a single fluorine substitutent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Citrate Cycle1930

Protein Targets (35)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gamma-aminobutyric acid receptor subunit piHomo sapiens (human)IC50 (µMol)263,027.00000.00011.02016.0000AID40995
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)IC50 (µMol)0.00160.00010.507510.0000AID40817; AID40826; AID42335
Gamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)IC50 (µMol)263,027.00000.00011.02016.0000AID40995
Gamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)IC50 (µMol)263,027.00000.00011.14948.0000AID40995
Gamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)Ki0.00260.00000.21085.6234AID1889906; AID219791; AID72640; AID72927
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)IC50 (µMol)0.00160.00010.507510.0000AID40817; AID40826; AID42335
Gamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)IC50 (µMol)263,027.00000.00011.03936.0000AID40995
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)IC50 (µMol)0.00160.00010.507510.0000AID40817; AID40826; AID42335
Gamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)IC50 (µMol)263,027.00000.00011.29158.0000AID40995
Gamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)Ki0.23790.00000.18819.0000AID1889906; AID1889907; AID1889908; AID1889909; AID219791; AID219938; AID219953; AID71266; AID71267; AID72640; AID72927; AID73077; AID73089; AID73232; AID73244; AID73523; AID73529
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)IC50 (µMol)0.00160.00010.505710.0000AID40817; AID40826; AID42335
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)IC50 (µMol)0.00160.00010.497310.0000AID40817; AID40826; AID42335
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)IC50 (µMol)0.00160.00010.507510.0000AID40817; AID40826; AID42335
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)IC50 (µMol)0.00160.00010.498810.0000AID40817; AID40826; AID42335
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)IC50 (µMol)0.00160.00010.504610.0000AID40817; AID40826; AID42335
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)IC50 (µMol)0.00160.00010.507510.0000AID40817; AID40826; AID42335
Gamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)IC50 (µMol)263,027.00000.00011.30188.0000AID40995
Gamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)Ki0.33580.00010.20769.0000AID219791; AID219938; AID219953; AID71266; AID71267; AID72927; AID73077; AID73089; AID73232; AID73244; AID73523; AID73529
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)IC50 (µMol)0.00160.00010.507510.0000AID40817; AID40826; AID42335
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)IC50 (µMol)0.00160.00010.507510.0000AID40817; AID40826; AID42335
Translocator proteinHomo sapiens (human)IC50 (µMol)263,027.00000.00030.13020.4900AID40987
Cholecystokinin receptor type ARattus norvegicus (Norway rat)IC50 (µMol)100.00000.00000.43624.3000AID52410; AID52413
Gastrin/cholecystokinin type B receptorRattus norvegicus (Norway rat)IC50 (µMol)100.00000.00010.24801.4000AID52410
Gamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)IC50 (µMol)263,027.00000.00010.98006.0000AID40995
Gamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)Ki0.00210.00010.24425.6234AID1889909; AID73523; AID73529
Gamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)IC50 (µMol)263,027.00000.00011.19936.0000AID40995
Gamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)Ki0.00480.00010.25155.6234AID1889908; AID219953; AID73232; AID73244
Gamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)IC50 (µMol)263,027.00000.00011.02016.0000AID40995
Gamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)Ki0.00210.00010.24015.6234AID1889907; AID219938; AID73077; AID73089
Gamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)IC50 (µMol)263,027.00000.00010.93746.0000AID40995
Gamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)Ki0.00300.00000.28325.6234AID1889906; AID1889907; AID1889908; AID1889909; AID72640
Gamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)IC50 (µMol)263,027.00000.00011.01936.0000AID40995
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)IC50 (µMol)0.00160.00010.506510.0000AID40817; AID40826; AID42335
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)IC50 (µMol)0.00160.00010.505710.0000AID40817; AID40826; AID42335
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)IC50 (µMol)0.00160.00010.507510.0000AID40817; AID40826; AID42335
Gamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)IC50 (µMol)263,027.00000.00011.02016.0000AID40995
Gamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)IC50 (µMol)263,027.00000.00011.02016.0000AID40995
Gamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)Ki2.00000.00020.41199.0000AID71266; AID71267
Gamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)IC50 (µMol)263,027.00000.00011.02016.0000AID40995
GABA theta subunitRattus norvegicus (Norway rat)IC50 (µMol)0.00160.00010.507510.0000AID40817; AID40826; AID42335
Gamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)IC50 (µMol)263,027.00000.00011.02016.0000AID40995
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)IC50 (µMol)0.00160.00010.507510.0000AID40817; AID40826; AID42335
Gamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)IC50 (µMol)263,027.00000.00011.02016.0000AID40995
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)EC50 (µMol)0.00140.00112.000910.0000AID385604
Gamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)Kd0.00450.00010.01020.0760AID343089
Gamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)EC50 (µMol)0.00140.00141.957810.0000AID385604
Gamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)Kd0.00300.00050.12830.8260AID343090
Gamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)EC50 (µMol)0.00140.00141.776810.0000AID385604
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (63)

Processvia Protein(s)Taxonomy
chloride transmembrane transportGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
monoatomic ion transportGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
response to toxic substanceGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
central nervous system neuron developmentGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
response to progesteroneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
ovulation cycleGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
post-embryonic developmentGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
adult behaviorGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
roof of mouth developmentGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
protein targeting to mitochondrionTranslocator proteinHomo sapiens (human)
C21-steroid hormone biosynthetic processTranslocator proteinHomo sapiens (human)
heme biosynthetic processTranslocator proteinHomo sapiens (human)
monoatomic anion transportTranslocator proteinHomo sapiens (human)
chloride transportTranslocator proteinHomo sapiens (human)
steroid metabolic processTranslocator proteinHomo sapiens (human)
glial cell migrationTranslocator proteinHomo sapiens (human)
response to xenobiotic stimulusTranslocator proteinHomo sapiens (human)
response to manganese ionTranslocator proteinHomo sapiens (human)
response to vitamin B1Translocator proteinHomo sapiens (human)
peripheral nervous system axon regenerationTranslocator proteinHomo sapiens (human)
sterol transportTranslocator proteinHomo sapiens (human)
adrenal gland developmentTranslocator proteinHomo sapiens (human)
negative regulation of protein ubiquitinationTranslocator proteinHomo sapiens (human)
regulation of cholesterol transportTranslocator proteinHomo sapiens (human)
response to progesteroneTranslocator proteinHomo sapiens (human)
negative regulation of tumor necrosis factor productionTranslocator proteinHomo sapiens (human)
response to testosteroneTranslocator proteinHomo sapiens (human)
regulation of cell population proliferationTranslocator proteinHomo sapiens (human)
cholesterol homeostasisTranslocator proteinHomo sapiens (human)
positive regulation of apoptotic processTranslocator proteinHomo sapiens (human)
negative regulation of nitric oxide biosynthetic processTranslocator proteinHomo sapiens (human)
behavioral response to painTranslocator proteinHomo sapiens (human)
regulation of steroid biosynthetic processTranslocator proteinHomo sapiens (human)
positive regulation of mitochondrial depolarizationTranslocator proteinHomo sapiens (human)
positive regulation of calcium ion transportTranslocator proteinHomo sapiens (human)
contact inhibitionTranslocator proteinHomo sapiens (human)
positive regulation of glial cell proliferationTranslocator proteinHomo sapiens (human)
negative regulation of glial cell proliferationTranslocator proteinHomo sapiens (human)
positive regulation of programmed necrotic cell deathTranslocator proteinHomo sapiens (human)
cellular response to lipopolysaccharideTranslocator proteinHomo sapiens (human)
cellular response to zinc ionTranslocator proteinHomo sapiens (human)
cellular hypotonic responseTranslocator proteinHomo sapiens (human)
maintenance of protein location in mitochondrionTranslocator proteinHomo sapiens (human)
negative regulation of mitophagyTranslocator proteinHomo sapiens (human)
negative regulation of ATP metabolic processTranslocator proteinHomo sapiens (human)
response to acetylcholineTranslocator proteinHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processTranslocator proteinHomo sapiens (human)
negative regulation of corticosterone secretionTranslocator proteinHomo sapiens (human)
behavioral fear responseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
associative learningGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
inner ear receptor cell developmentGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
innervationGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
cochlea developmentGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
inner ear receptor cell developmentGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
innervationGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
cochlea developmentGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
negative regulation of chloride transportGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
response to xenobiotic stimulusGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
neurotransmitter transportGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (20)

Processvia Protein(s)Taxonomy
GABA-A receptor activityGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
GABA receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
ligand-gated monoatomic ion channel activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA receptor bindingGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
G protein-coupled neurotransmitter receptor activity involved in regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
identical protein bindingGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
androgen bindingTranslocator proteinHomo sapiens (human)
protein bindingTranslocator proteinHomo sapiens (human)
benzodiazepine receptor activityTranslocator proteinHomo sapiens (human)
cholesterol bindingTranslocator proteinHomo sapiens (human)
transmembrane transporter bindingTranslocator proteinHomo sapiens (human)
cholesterol transfer activityTranslocator proteinHomo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
signaling receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA receptor bindingGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA receptor activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
GABA receptor bindingGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
transmembrane signaling receptor activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
neurotransmitter transmembrane transporter activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (36)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
apical plasma membraneGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
axonGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
dendriteGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
neuronal cell bodyGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA receptor complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
nuclear envelopeGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
dendriteGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
presynaptic active zone membraneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
Schaffer collateral - CA1 synapseGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
axonGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
mitochondrionTranslocator proteinHomo sapiens (human)
mitochondrial outer membraneTranslocator proteinHomo sapiens (human)
cytosolTranslocator proteinHomo sapiens (human)
intracellular membrane-bounded organelleTranslocator proteinHomo sapiens (human)
extracellular exosomeTranslocator proteinHomo sapiens (human)
endoplasmic reticulumTranslocator proteinHomo sapiens (human)
membraneTranslocator proteinHomo sapiens (human)
nucleoplasmGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
cytosolGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
neuronal cell body membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
presynaptic membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
axonGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
synaptic vesicle membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
neuronal cell bodyGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
inhibitory synapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
extracellular exosomeGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
postsynaptic membraneGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
cerebellar Golgi cell to granule cell synapseGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
nucleolusGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
microtubule cytoskeletonGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
receptor complexGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (93)

Assay IDTitleYearJournalArticle
AID1301531Selectivity ratio, ratio of Ki for central-type benzodiazepine receptor in bovine cortical membrane to Ki for central-type benzodiazepine receptor in bovine cortical membrane in presence of 50 uM of GABA2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Design, Synthesis, and Biological Evaluation of Imidazo[1,5-a]quinoline as Highly Potent Ligands of Central Benzodiazepine Receptors.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID385604Activity at human GABAA alpha-1-beta-2-gamma-2S327 receptor in HEK293 cells expressing as-PKCepsilon cells assessed as evoked current response by whole cell patch clamp method2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2 subunits.
AID226385Displacement of [3H]flunitrazepam from GABA-A benzodiazepine receptor of rat cerebral cortex membrane1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
Synthesis of beta-carboline-benzodiazepine hybrid molecules: use of the known structural requirements for benzodiazepine and beta-carboline binding in designing a novel, high-affinity ligand for the benzodiazepine receptor.
AID26304Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID385594Activity at human GABAA alpha-1-beta-2-gamma-2 LS327A,S343A receptor in HEK293 cells expressing as-PKCepsilon assessed as evoked current response by whole cell patch clamp method2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2 subunits.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID229422Selectivity of binding to pancreatic CCK and brain benzodiazepine receptors, ratio of IC501987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
Design of nonpeptidal ligands for a peptide receptor: cholecystokinin antagonists.
AID52280Half-maximal inhibition of [125I]-CCK-8(+) binding to cholecystokinin receptor from guinea pig brain tissue1988Journal of medicinal chemistry, Dec, Volume: 31, Issue:12
Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists.
AID1150164Anticonvulsion activity in mouse assessed as protection against pentylenetetrazole-induced convulsion1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Electronic factors in the structure-activity relationship of some 1,4-benzodiazepin-2-ones.
AID1889906Displacement of [3H]flunitrazepam from human recombinant alpha1beta2gamma2 GABAA receptor expressed in HEK cell membrane by competitive radioligand binding assay2022Bioorganic & medicinal chemistry letters, 04-15, Volume: 62Rationalizing the binding and α subtype selectivity of synthesized imidazodiazepines and benzodiazepines at GABAA receptors by using molecular docking studies.
AID219791Binding affinity measured using LtK- cell membranes expressing GABA alpha-1-beta-3-gamma-2 receptor1998Journal of medicinal chemistry, Jul-02, Volume: 41, Issue:14
Synthesis and evaluation of analogues of the partial agonist 6-(propyloxy)-4-(methoxymethyl)-beta-carboline-3-carboxylic acid ethyl ester (6-PBC) and the full agonist 6-(benzyloxy)-4-(methoxymethyl)-beta-carboline-3-carboxylic acid ethyl ester (Zk 93423)
AID13306-Log C was determined by performing the incl screen test1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Decomposition of pharmacological activity indices into mutually independent components using principal component analysis.
AID385595Activity at human GABAA alpha-1-beta-2-gamma-2 LS327A receptor in HEK293 cells expressing as-PKCepsilon assessed as evoked current response by whole cell patch clamp method2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2 subunits.
AID1150163Taming activity in mouse assessed as suppression of electrical current-induced aggressive behavior by foot-shock test1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Electronic factors in the structure-activity relationship of some 1,4-benzodiazepin-2-ones.
AID73244Binding affinity for human recombinant gamma-aminobutyric-acid (GABA) A receptor alpha-3-beta-3-gamma-22000Journal of medicinal chemistry, Jan-13, Volume: 43, Issue:1
Pharmacophore/receptor models for GABA(A)/BzR subtypes (alpha1beta3gamma2, alpha5beta3gamma2, and alpha6beta3gamma2) via a comprehensive ligand-mapping approach.
AID40987Binding affinity of compound towards Benzodiazepine receptor in a competition assay1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Genetic neural networks for quantitative structure-activity relationships: improvements and application of benzodiazepine affinity for benzodiazepine/GABAA receptors.
AID72640Binding affinity evaluated by ability to displace [3H]Ro-151788 from recombinant human Gamma-aminobutyric acid A receptor alpha-1-beta-2-gamma-2 expressed in L(tk-)cells2000Bioorganic & medicinal chemistry letters, Jun-19, Volume: 10, Issue:12
N-(indol-3-ylglyoxylyl)piperidines: high affinity agonists of human GABA-A receptors containing the alpha1 subunit.
AID71267Binding affinity measured using LtK- cell membranes expressing Gamma-aminobutyric acid A receptor alpha-6-beta-3-gamma-21998Journal of medicinal chemistry, Jul-02, Volume: 41, Issue:14
Synthesis and evaluation of analogues of the partial agonist 6-(propyloxy)-4-(methoxymethyl)-beta-carboline-3-carboxylic acid ethyl ester (6-PBC) and the full agonist 6-(benzyloxy)-4-(methoxymethyl)-beta-carboline-3-carboxylic acid ethyl ester (Zk 93423)
AID42335Displacement of [3H]diazepam from GABA-A Benzodiazepine receptor of rat forebrain1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and benzodiazepine binding activity of a series of novel [1,2,4]triazolo[1,5-c]quinazolin-5(6H)-ones.
AID52413Half-maximal inhibition of [125I]CCK-33 binding to cholecystokinin A receptor from rat pancreatic tissue1988Journal of medicinal chemistry, Dec, Volume: 31, Issue:12
Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists.
AID73089Binding affinity to human recombinant gamma-aminobutyric-acid (GABA) A receptor alpha-2-beta-3-gamma-22000Journal of medicinal chemistry, Jan-13, Volume: 43, Issue:1
Pharmacophore/receptor models for GABA(A)/BzR subtypes (alpha1beta3gamma2, alpha5beta3gamma2, and alpha6beta3gamma2) via a comprehensive ligand-mapping approach.
AID13304-Log C was determined by performing the electroshock minimum test1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Decomposition of pharmacological activity indices into mutually independent components using principal component analysis.
AID701024Ratio of Ki for central benzodiazepine receptor in human cortical membrane to Ki for central benzodiazepine receptor in human cortical membrane in presence of 50 uM GABA2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
New insight into the central benzodiazepine receptor-ligand interactions: design, synthesis, biological evaluation, and molecular modeling of 3-substituted 6-phenyl-4H-imidazo[1,5-a][1,4]benzodiazepines and related compounds.
AID365608Displacement of [3H]flumazenil from CBR in bovine cortical membrane2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Ethyl 8-fluoro-6-(3-nitrophenyl)-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate as novel, highly potent, and safe antianxiety agent.
AID385593Activity at human GABAA alpha1beta2 S410A-gamma-2-LS327A,S343A receptor in HEK293 cells expressing as-PKCepsilon assessed as evoked current response by whole cell patch clamp method2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2 subunits.
AID13308-Log C was determined by performing the pentylenetetrazole test1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Decomposition of pharmacological activity indices into mutually independent components using principal component analysis.
AID701023Ratio of Ki for central benzodiazepine receptor in bovine cortical membrane to Ki for central benzodiazepine receptor in bovine cortical membrane in presence of 50 uM GABA2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
New insight into the central benzodiazepine receptor-ligand interactions: design, synthesis, biological evaluation, and molecular modeling of 3-substituted 6-phenyl-4H-imidazo[1,5-a][1,4]benzodiazepines and related compounds.
AID1889908Displacement of [3H]flunitrazepam from human recombinant alpha3beta2gamma2 GABAA receptor expressed in HEK cell membrane by competitive radioligand binding assay2022Bioorganic & medicinal chemistry letters, 04-15, Volume: 62Rationalizing the binding and α subtype selectivity of synthesized imidazodiazepines and benzodiazepines at GABAA receptors by using molecular docking studies.
AID227698Evaluation for the Anti-pentylenetetrazole effect.1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Neural networks applied to quantitative structure-activity relationship analysis.
AID71266Binding affinity for human recombinant gamma-aminobutyric-acid (GABA) A receptor alpha-6-beta-3-gamma-22000Journal of medicinal chemistry, Jan-13, Volume: 43, Issue:1
Pharmacophore/receptor models for GABA(A)/BzR subtypes (alpha1beta3gamma2, alpha5beta3gamma2, and alpha6beta3gamma2) via a comprehensive ligand-mapping approach.
AID40817Displacement of [3H]diazepam from rat brain GABA-A benzodiazepine receptor1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
Design of nonpeptidal ligands for a peptide receptor: cholecystokinin antagonists.
AID385601Activity of human GABA alpha-1-beta-2-gamma-2 LS327A mutant in HEK293 cells assessed as activation of current at 300 nM2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2 subunits.
AID1889909Displacement of [3H]flunitrazepam from human recombinant alpha5beta2gamma2 GABAA receptor expressed in HEK cell membrane by competitive radioligand binding assay2022Bioorganic & medicinal chemistry letters, 04-15, Volume: 62Rationalizing the binding and α subtype selectivity of synthesized imidazodiazepines and benzodiazepines at GABAA receptors by using molecular docking studies.
AID40827Displacement of [3H]beta-CCE from GABA-A benzodiazepine receptor of rat cerebral cortex membranes1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
Synthesis of beta-carboline-benzodiazepine hybrid molecules: use of the known structural requirements for benzodiazepine and beta-carboline binding in designing a novel, high-affinity ligand for the benzodiazepine receptor.
AID40995Binding affinity towards benzodiazepine/GABA A receptor.1995Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
Prediction of receptor properties and binding affinity of ligands to benzodiazepine/GABAA receptors using artificial neural networks.
AID13307-Log C was determined by performing the maximum electroshock test1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Decomposition of pharmacological activity indices into mutually independent components using principal component analysis.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1150162Muscle relaxant activity in mouse1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Electronic factors in the structure-activity relationship of some 1,4-benzodiazepin-2-ones.
AID73232Binding affinity evaluated by ability to displace [3H]Ro-151788 from recombinant human Gamma-aminobutyric acid A receptor alpha-3-beta-3-gamma-2 expressed in L(tk-)cells2000Bioorganic & medicinal chemistry letters, Jun-19, Volume: 10, Issue:12
N-(indol-3-ylglyoxylyl)piperidines: high affinity agonists of human GABA-A receptors containing the alpha1 subunit.
AID139100Logarithm of effective dose evaluated using the foot-shock test in mice1983Journal of medicinal chemistry, Aug, Volume: 26, Issue:8
Quantitative structure-activity relationships employing independent quantum chemical indices.
AID343090Binding affinity to GABAA alpha-5-beta-2-gamma-2 receptor2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Selective influence on contextual memory: physiochemical properties associated with selectivity of benzodiazepine ligands at GABAA receptors containing the alpha5 subunit.
AID1849525Binding affinity to CBR (unknown origin)2021European journal of medicinal chemistry, Jan-01, Volume: 209An update into the medicinal chemistry of translocator protein (TSPO) ligands.
AID365610Ratio of Ki for bovine CBR in absence of GABA to Ki for bovine CBR in presence of 50 uM GABA2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Ethyl 8-fluoro-6-(3-nitrophenyl)-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate as novel, highly potent, and safe antianxiety agent.
AID1889907Displacement of [3H]flunitrazepam from human recombinant alpha2beta2gamma2 GABAA receptor expressed in HEK cell membrane by competitive radioligand binding assay2022Bioorganic & medicinal chemistry letters, 04-15, Volume: 62Rationalizing the binding and α subtype selectivity of synthesized imidazodiazepines and benzodiazepines at GABAA receptors by using molecular docking studies.
AID232605Ratio of IC50 CCK(pancreas)/ IC50BZD (brain)1988Journal of medicinal chemistry, Dec, Volume: 31, Issue:12
Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists.
AID73529Binding affinity measured using LtK- cell membranes expressing Gamma-aminobutyric acid A receptor alpha-5-beta-3-gamma-21998Journal of medicinal chemistry, Jul-02, Volume: 41, Issue:14
Synthesis and evaluation of analogues of the partial agonist 6-(propyloxy)-4-(methoxymethyl)-beta-carboline-3-carboxylic acid ethyl ester (6-PBC) and the full agonist 6-(benzyloxy)-4-(methoxymethyl)-beta-carboline-3-carboxylic acid ethyl ester (Zk 93423)
AID343089Binding affinity to GABAA alpha-1-beta-2-gamma-2 receptor2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Selective influence on contextual memory: physiochemical properties associated with selectivity of benzodiazepine ligands at GABAA receptors containing the alpha5 subunit.
AID1150165Muscle relaxant activity in cat suspended by scruff of neck assessed as relaxation of body and hind legs1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Electronic factors in the structure-activity relationship of some 1,4-benzodiazepin-2-ones.
AID1150161Sedative activity in mouse1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Electronic factors in the structure-activity relationship of some 1,4-benzodiazepin-2-ones.
AID385596Activity at human GABAA alpha-1-beta-2-S410A-gamma-2L receptor in HEK293 cells expressing as-PKCepsilon assessed as evoked current response by whole cell patch clamp method2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2 subunits.
AID1301538Partial inverse agonist activity at central-type benzodiazepine receptor in Sprague-Dawley rat cerebrocortical synaptoneurosomes assessed as decrease in 36Cl- flow after 10 secs by liquid-phase scintillation beta-counting method2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Design, Synthesis, and Biological Evaluation of Imidazo[1,5-a]quinoline as Highly Potent Ligands of Central Benzodiazepine Receptors.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID232720Selectivity ratio of alpha1 beta-3 gamma2 GABA A / BzR and alpha5 beta-3 gamma2 GABA A / BzR2000Journal of medicinal chemistry, Jan-13, Volume: 43, Issue:1
Pharmacophore/receptor models for GABA(A)/BzR subtypes (alpha1beta3gamma2, alpha5beta3gamma2, and alpha6beta3gamma2) via a comprehensive ligand-mapping approach.
AID72927Binding affinity for human recombinant gamma-aminobutyric-acid (GABA) A receptor alpha-1-beta-3-gamma-22000Journal of medicinal chemistry, Jan-13, Volume: 43, Issue:1
Pharmacophore/receptor models for GABA(A)/BzR subtypes (alpha1beta3gamma2, alpha5beta3gamma2, and alpha6beta3gamma2) via a comprehensive ligand-mapping approach.
AID701026Agonist activity at central benzodiazepine receptor in Sprague-Dawley rat cerebrocortical synaptoneurosomes assessed as increase in GABA-induced [36]chloride ion flow after 10 seconds by beta liquid scintillation counting2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
New insight into the central benzodiazepine receptor-ligand interactions: design, synthesis, biological evaluation, and molecular modeling of 3-substituted 6-phenyl-4H-imidazo[1,5-a][1,4]benzodiazepines and related compounds.
AID13305-Log C was determined by performing the foot shock test1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Decomposition of pharmacological activity indices into mutually independent components using principal component analysis.
AID73523Binding affinity for human recombinant gamma-aminobutyric-acid (GABA) A receptor alpha-5-beta-3-gamma-22000Journal of medicinal chemistry, Jan-13, Volume: 43, Issue:1
Pharmacophore/receptor models for GABA(A)/BzR subtypes (alpha1beta3gamma2, alpha5beta3gamma2, and alpha6beta3gamma2) via a comprehensive ligand-mapping approach.
AID40826Inhibition of [3H]diazepam binding to GABA-A benzodiazepine receptor of rat brain1988Journal of medicinal chemistry, Dec, Volume: 31, Issue:12
Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists.
AID29360Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1301535Selectivity ratio, ratio of Ki for central-type benzodiazepine receptor in human cortical membrane to Ki for central-type benzodiazepine receptor in human cortical membrane in presence of 50 uM of GABA2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Design, Synthesis, and Biological Evaluation of Imidazo[1,5-a]quinoline as Highly Potent Ligands of Central Benzodiazepine Receptors.
AID22293Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID701022Displacement of [3H]flumazenil from central benzodiazepine receptor in human cortical membrane after 90 mins by beta liquid scintillation counting2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
New insight into the central benzodiazepine receptor-ligand interactions: design, synthesis, biological evaluation, and molecular modeling of 3-substituted 6-phenyl-4H-imidazo[1,5-a][1,4]benzodiazepines and related compounds.
AID701021Displacement of [3H]flumazenil from central benzodiazepine receptor in bovine cortical membrane after 90 mins by beta liquid scintillation counting2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
New insight into the central benzodiazepine receptor-ligand interactions: design, synthesis, biological evaluation, and molecular modeling of 3-substituted 6-phenyl-4H-imidazo[1,5-a][1,4]benzodiazepines and related compounds.
AID52275Half-maximal inhibition of [125I]CCK-33 binding to guinea pig brain(cortex) cholecystokinin receptor1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
Design of nonpeptidal ligands for a peptide receptor: cholecystokinin antagonists.
AID539464Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID385600Activity of human GABA alpha-1-beta-2-gamma-2L receptor in HEK293 cells assessed as activation of current at 300 nM2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2 subunits.
AID227697Compound was evaluated for the Anti-fighting behavior.1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Neural networks applied to quantitative structure-activity relationship analysis.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID228469Evaluation of inclined screen test.1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Neural networks applied to quantitative structure-activity relationship analysis.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID52410Half-maximal inhibition of [125I]-CCK-33 binding to rat pancreas cholecystokinin receptor1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
Design of nonpeptidal ligands for a peptide receptor: cholecystokinin antagonists.
AID365611Ratio of Ki for human CBR in absence of GABA to Ki for human CBR in presence of 50 uM GABA2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Ethyl 8-fluoro-6-(3-nitrophenyl)-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate as novel, highly potent, and safe antianxiety agent.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID72448Ability to affect GABA-induced chloride current in Xenopus oocytes transiently expressing human GABA-A alpha-1-beta-2-gamma-2 receptors using two-electrode voltage-clamp electrophysiology at test concentration of 1 uM2000Bioorganic & medicinal chemistry letters, Jun-19, Volume: 10, Issue:12
N-(indol-3-ylglyoxylyl)piperidines: high affinity agonists of human GABA-A receptors containing the alpha1 subunit.
AID385603Activity of human GABA alpha-1-beta-2-gamma-2 LS327A mutant in HEK293 cells assessed as inactivation of current at 300 nM2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2 subunits.
AID365609Displacement of [3H]flumazenil from CBR in human cortical membrane2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Ethyl 8-fluoro-6-(3-nitrophenyl)-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate as novel, highly potent, and safe antianxiety agent.
AID243422log (1/Km) value for human liver microsome cytochrome P450 3A42005Bioorganic & medicinal chemistry letters, Sep-15, Volume: 15, Issue:18
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
AID624647Inhibition of AZT glucuronidation by human UGT enzymes from liver microsomes2005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID1301529Displacement of [3H]-flumazenil from central-type benzodiazepine receptor in bovine cortical membrane after 90 mins by liquid-phase scintillation beta-counting method2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Design, Synthesis, and Biological Evaluation of Imidazo[1,5-a]quinoline as Highly Potent Ligands of Central Benzodiazepine Receptors.
AID672795Displacement of [3H]flumazenil from central benzodiazepine receptor in rat cerebral cortex membranes at 10 uM after 90 mins by competitive binding assay2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Synthesis and biological evaluation of 4-phenylquinazoline-2-carboxamides designed as a novel class of potent ligands of the translocator protein.
AID219938Binding affinity measured using LtK- cell membranes expressing GABA alpha-2-beta-3-gamma-2 receptor1998Journal of medicinal chemistry, Jul-02, Volume: 41, Issue:14
Synthesis and evaluation of analogues of the partial agonist 6-(propyloxy)-4-(methoxymethyl)-beta-carboline-3-carboxylic acid ethyl ester (6-PBC) and the full agonist 6-(benzyloxy)-4-(methoxymethyl)-beta-carboline-3-carboxylic acid ethyl ester (Zk 93423)
AID219953Binding affinity measured using LtK- cell membranes expressing GABA alpha-3-beta-3-gamma-2 receptor1998Journal of medicinal chemistry, Jul-02, Volume: 41, Issue:14
Synthesis and evaluation of analogues of the partial agonist 6-(propyloxy)-4-(methoxymethyl)-beta-carboline-3-carboxylic acid ethyl ester (6-PBC) and the full agonist 6-(benzyloxy)-4-(methoxymethyl)-beta-carboline-3-carboxylic acid ethyl ester (Zk 93423)
AID1301534Displacement of [3H]-flumazenil from central-type benzodiazepine receptor in human cortical membrane after 90 mins by liquid-phase scintillation beta-counting method2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Design, Synthesis, and Biological Evaluation of Imidazo[1,5-a]quinoline as Highly Potent Ligands of Central Benzodiazepine Receptors.
AID73077Binding affinity evaluated by ability to displace [3H]-Ro-15-1788 from recombinant human Gamma-aminobutyric acid A receptor alpha-2-beta-3-gamma-2 expressed in L(tk-)cells2000Bioorganic & medicinal chemistry letters, Jun-19, Volume: 10, Issue:12
N-(indol-3-ylglyoxylyl)piperidines: high affinity agonists of human GABA-A receptors containing the alpha1 subunit.
AID385592Activity at human GABAA alpha-1-beta-2-gamma-2L receptor in HEK293 cells expressing as-PKCepsilon assessed as evoked current response by whole cell patch clamp method2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2 subunits.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID385602Activity of human GABA alpha-1-beta-2-gamma-2Lreceptor in HEK293 cells assessed as inactivation of current at 300 nM2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2 subunits.
AID1346504Human GABAA receptor alpha2 subunit (GABAA receptors)1996Molecular pharmacology, Feb, Volume: 49, Issue:2
Cloning of cDNAs encoding the human gamma-aminobutyric acid type A receptor alpha 6 subunit and characterization of the pharmacology of alpha 6-containing receptors.
AID1346496Human GABAA receptor alpha3 subunit (GABAA receptors)1996Molecular pharmacology, Feb, Volume: 49, Issue:2
Cloning of cDNAs encoding the human gamma-aminobutyric acid type A receptor alpha 6 subunit and characterization of the pharmacology of alpha 6-containing receptors.
AID1346513Human GABAA receptor alpha5 subunit (GABAA receptors)1996Molecular pharmacology, Feb, Volume: 49, Issue:2
Cloning of cDNAs encoding the human gamma-aminobutyric acid type A receptor alpha 6 subunit and characterization of the pharmacology of alpha 6-containing receptors.
AID1346520Human GABAA receptor alpha1 subunit (GABAA receptors)1996Molecular pharmacology, Feb, Volume: 49, Issue:2
Cloning of cDNAs encoding the human gamma-aminobutyric acid type A receptor alpha 6 subunit and characterization of the pharmacology of alpha 6-containing receptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,557)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901287 (50.33)18.7374
1990's780 (30.50)18.2507
2000's341 (13.34)29.6817
2010's132 (5.16)24.3611
2020's17 (0.66)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 72.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index72.14 (24.57)
Research Supply Index8.01 (2.92)
Research Growth Index4.17 (4.65)
Search Engine Demand Index130.40 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (72.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials298 (11.05%)5.53%
Reviews69 (2.56%)6.00%
Case Studies96 (3.56%)4.05%
Observational0 (0.00%)0.25%
Other2,234 (82.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]